HC Wainwright Reiterates Buy Rating on Mineralys Therapeutics
HC Wainwright reiterated its Buy rating and $56 price target on Mineralys Therapeutics. The target implies 139.6% upside from the Oct. 9 close of $23.37.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.